# Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma

> **NCT02965716** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (actual)

## Conditions studied

- Advanced Melanoma
- Recurrent Melanoma
- Stage III Cutaneous Melanoma AJCC v7
- Stage IIIA Cutaneous Melanoma AJCC v7
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Unresectable Melanoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Talimogene Laherparepvec

## Key facts

- **NCT ID:** NCT02965716
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-05
- **Primary completion:** 2023-06-30
- **Final completion:** 2026-11-04
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965716, "Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02965716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*